Stock ONCT ONCTERNAL THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Analyst Reco. Oncternal Therapeutics, Inc.

Equities

ONCT

US68236P2065

Market Closed - Nasdaq
Other stock markets
 04:30:00 2024-06-05 pm EDT 		5-day change 1st Jan Change
8.8 USD +6.02% Intraday chart for Oncternal Therapeutics, Inc. -3.40% -17.94%
May. 30 Oncternal Announces Enrollment Completed and Dosing Initiated for Fifth Dose Cohort of Phase 1/2 Study of Onct-534 for the Treatment of R/R Metastatic Castration-Resistant Prostate Cancer CI
May. 09 Transcript : Oncternal Therapeutics, Inc., Q1 2024 Earnings Call, May 09, 2024

Analyst Reco.

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
HC Wainwright Cuts Oncternal Therapeutics' Price Target to $28 From $30, Keeps Buy Rating
MT
Brookline Capital Upgrades Oncternal Therapeutics to Buy From Hold, Price Target is $2
MT
HC Wainwright Upgrades Oncternal Therapeutics to Buy From Neutral, Price Target is $2
MT
Maxim Downgrades Oncternal Therapeutics to Hold From Buy
MT
Oppenheimer Downgrades Oncternal Therapeutics to Perform From Outperform, Removes $9 Price Target
MT
Brookline Capital Downgrades Oncternal Therapeutics to Hold From Buy
MT
Cantor Fitzgerald Adjusts Price Target on Oncternal Therapeutics to $1.30 From $4, Keeps Overweight Rating
MT
HC Wainwright Downgrades Oncternal Therapeutics to Neutral From Buy
MT
Oppenheimer Adjusts Oncternal Therapeutics Price Target to $9 From $14, Maintains Outperform Rating
MT
Cantor Fitzgerald Initiates Oncternal Therapeutics With Overweight Rating, $4 Price Target
MT
Maxim Initiates Oncternal Therapeutics at Buy, Sets Price Target at $3.50
MT
BTIG Starts Oncternal Therapeutics at Buy With $5 Price Target
MT
ONCTERNAL THERAPEUTICS : Oppenheimer Adjusts Oncternal Therapeutics PT to $16 From $14, Maintains Outperform Rating
MT
ONCTERNAL THERAPEUTICS : Oppenheimer Starts Oncternal Therapeutics at Outperform with $14 Price Target
MT
ONCTERNAL THERAPEUTICS : Brookline Capital Initiates Coverage on Oncternal Therapeutics With Buy Rating, $16 Price Target
MT
ONCTERNAL THERAPEUTICS : Northland Starts Oncternal Therapeutics at Outperform With $21 Price Target
MT
Oncternal Therapeutics, Inc. Announces Interim Clinical Data Update, Including 50% Complete Response Rate, for Cirmtuzumab in Combination with Ibrutinib in Patients with Mantle Cell Lymphoma
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. ONCT Stock
  4. News Oncternal Therapeutics, Inc.
  5. Analyst Reco.